PFPeptide File
Live Updates
NEWRetatrutide Phase III results — 28.7% body weight reduction confirmed at 12mg/68 weeks·UPDATECJC-1295 half-life study published in Journal of Endocrinology·TRIALBPC-157 human trial enrolment opens Q3 2026·FDARetatrutide NDA submission expected late 2026·RESEARCHNew GLP-1/GIP dual agonist data vs tirzepatide head-to-head·NEWRetatrutide Phase III results — 28.7% body weight reduction confirmed at 12mg/68 weeks·UPDATECJC-1295 half-life study published in Journal of Endocrinology·TRIALBPC-157 human trial enrolment opens Q3 2026·FDARetatrutide NDA submission expected late 2026·RESEARCHNew GLP-1/GIP dual agonist data vs tirzepatide head-to-head·
Recovery & Healing Peptide

The BPC-157 File

Research compound (not FDA approved) · N/A — research peptide

Moderate Evidence

The most popular recovery peptide. Strong animal study data for tendon, ligament, and gut healing. Human clinical data is limited but growing.

Mechanism

Gastric pentadecapeptide that promotes angiogenesis, tendon and ligament healing, and gut repair

Key Data

primary Use

Injury recovery, gut healing, tendon repair

evidence Base

Extensive animal studies, limited human trials

administration Routes

  • · Subcutaneous injection
  • · Oral

common Side Effects

  • · Generally well-tolerated in studies
  • · Injection site reactions

Full Article Coming Soon

The full The BPC-157 File will cover mechanism of action, clinical trial evidence, dosage data, side effects, comparisons, and FAQs — all evidence-rated and referenced. Check back soon.

This content is for informational purposes only. Not medical advice. Always consult a qualified healthcare provider before making any health decisions.

The weekly peptide brief.

One email per week. Evidence-rated research summaries on peptides and metabolic science. No hype. No selling. Unsubscribe anytime.

No spam. No selling. Unsubscribe with one click.